Truist Financial Boosts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $230.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target boosted by stock analysts at Truist Financial from $220.00 to $230.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Truist Financial’s price target suggests a potential upside of 65.69% from the company’s current price.

Other equities analysts have also recently issued reports about the company. Barclays reissued an “overweight” rating and set a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. JPMorgan Chase & Co. boosted their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Cantor Fitzgerald cut Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and boosted their target price for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. Robert W. Baird boosted their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research note on Monday, November 18th. Finally, Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Buy” and an average target price of $189.40.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $138.81 on Thursday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals has a fifty-two week low of $99.06 and a fifty-two week high of $148.06. The stock has a 50 day moving average price of $128.14 and a two-hundred day moving average price of $120.00. The company has a market capitalization of $8.43 billion, a P/E ratio of 19.55, a PEG ratio of 1.04 and a beta of 0.44.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CMO Robert Iannone sold 7,080 shares of the business’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the sale, the chief marketing officer now directly owns 82,024 shares of the company’s stock, valued at approximately $11,368,526.40. The trade was a 7.95 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the sale, the chief executive officer now directly owns 439,744 shares in the company, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 25,193 shares of company stock valued at $3,533,122. 4.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. IFP Advisors Inc bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $25,000. Quadrant Capital Group LLC lifted its holdings in shares of Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares in the last quarter. Elequin Capital LP lifted its holdings in shares of Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 183 shares in the last quarter. CoreFirst Bank & Trust bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $28,000. Finally, Allianz SE bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $29,000. 89.14% of the stock is owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.